Get started
Whitehawk Therapeutics, Inc.Whitehawk Therapeutics, Inc.Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals Options

WHWK fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Morristown, NJ.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
WHWK has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company